EU's drug regulator has recommended that Pfizer’s coronavirus drug be authorized for use in the 27-nation European Union, the first time the agency has recommended a COVID-19 pill. The drug was cleared by regulators in the U.S. and Britain in December.
AMSTERDAM — The European Medicines Agency has recommended that Pfizer’s coronavirus antiviral drug be authorized for use in the 27-nation European Union, the first time the agency has recommended a pill for treating COVID-19.
In a statement on Thursday, the EU drug regulator said giving the green light to Pfizer’s Paxlovoid could help people infected with COVID-19 avoid more serious disease and being hospitalized. EMA’s expert committee recommended the pill be given to adults who don’t require oxygen and who are at higher risk of severe disease.
The drug was cleared by regulators in the U.S. and Britain in late December, although authorities noted that supplies would be extremely limited. An antiviral pill from Merck also is expected to soon be authorized. But Pfizer’s drug is all but certain to be the preferred option because of its mild side effects and superior effectiveness as suggested by studies, including a nearly 90% reduction in hospitalizations and deaths among patients most likely to get severely ill.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Leer más »
Pfizer opens study of COVID shots updated to match omicronPfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the hugely contagious omicron variant. Pfizer...
Leer más »
Pfizer, BioNTech begin omicron-specific COVID-19 vaccine studyCOVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.
Leer más »
Pfizer opens study of COVID shots updated to match omicronPfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant.
Leer más »
Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Leer más »
Pfizer opens study of COVID shots updated to match omicronThe original vaccines still offer good protection against severe illness and death. Studies in the U.S. and elsewhere have made clear that adding a booster dose strengthens that protection and improves the chances of avoiding a milder infection.
Leer más »